Q1 2026 Dare Bioscience Inc Earnings Call Transcript

May 14, 2026 / 08:30 PM GMT

Release Date Price: $2.86 (+0.70%)

Transcript 10-Q8-K

Key Points

Positve

Dare Bioscience Inc (DARE) has a comprehensive pipeline focused exclusively on women's health, addressing critical gaps in care.
The company is launching its first direct product revenue with FloraSync LF5 in June 2026, marking a significant milestone.
Dare to Play, a first-of-its-kind topical arousal cream for women, has received enthusiastic reception from healthcare providers.
The company benefits from non-dilutive grant funding, which helps advance multiple programs while managing shareholder dilution.
Dare Bioscience Inc (DARE) is strategically positioned with a dual-path approach, pursuing both 503b compounding and FDA approval for its products.

Negative

The launch of Dare to Play has faced delays due to state-specific registration activities and manufacturing readiness.
The company does not have 12 months of capital on hand and will need to raise additional funds.
There are some states that will not allow dispensing of Dare to Play until they review data from other states.
The company is still in the process of building its commercial infrastructure, which may impact the speed of market penetration.
Oviprine, a potential first-in-category product, still requires further clinical trials and FDA engagement, which could delay its market entry.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

DARE.OQ - Dare Bioscience Inc
Q1 2026 Dare Bioscience Inc Earnings Call
May 14, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, thank you for standing by. Hello, and welcome to the conference call hosted by Dairy Bioscience to review the company's first quarter 2026 financial results and to provide a business update.

This call is being recorded. My name is King and I will be your operator today. With us today from DARE are Sabrina Matucci-Johnson, President and Chief Executive Officer, and Marty Herring-Layton, Chief Accounting Officer.

Ms. Herring-Layton, please proceed.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good afternoon and welcome to the DARE Bioscience

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.